Index RUT P/E - EPS (ttm) -1.50 Insider Own 18.97% Shs Outstand 256.14M Perf Week 4.52%
Market Cap 2.61B Forward P/E - EPS next Y -0.83 Insider Trans -0.09% Shs Float 246.97M Perf Month -19.03%
Income -410.00M PEG - EPS next Q -0.26 Inst Own 68.45% Short Float 24.19% Perf Quarter -28.15%
Sales 90.86M P/S 28.68 EPS this Y 33.29% Inst Trans 9.99% Short Ratio 9.59 Perf Half Y -14.59%
Book/sh 2.54 P/B 3.37 EPS next Y 34.44% ROA -44.48% Short Interest 59.73M Perf Year 58.48%
Cash/sh 1.30 P/C 6.56 EPS next 5Y - ROE -56.65% 52W Range 5.24 - 18.33 Perf YTD 5.17%
Dividend Est. - P/FCF - EPS past 5Y -8.25% ROI -48.76% 52W High -53.36% Beta 0.54
Dividend TTM - Quick Ratio 3.90 Sales past 5Y 0.00% Gross Margin -19.74% 52W Low 63.17% ATR (14) 0.66
Dividend Ex-Date - Current Ratio 4.22 EPS Y/Y TTM 28.07% Oper. Margin -473.22% RSI (14) 38.85 Volatility 5.09% 6.43%
Employees 557 Debt/Eq 0.10 Sales Y/Y TTM 12751.20% Profit Margin -451.25% Recom 1.40 Target Price 23.77
Option/Short Yes / Yes LT Debt/Eq 0.09 EPS Q/Q 40.47% Payout - Rel Volume 1.32 Prev Close 8.24
Sales Surprise 8.87% EPS Surprise 6.32% Sales Q/Q 12385.07% Earnings Nov 07 AMC Avg Volume 6.23M Price 8.55
SMA20 -14.62% SMA50 -13.74% SMA200 -20.71% Trades
Volume 8,219,400 Change 3.76%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-24-24 Initiated UBS
Buy
$17
Jul-29-24 Downgrade Piper Sandler
Overweight → Neutral
$19 → $10
Nov-20-23 Initiated Goldman
Buy
$12
Sep-18-23 Reiterated Barclays
Overweight
$40 → $18
May-30-23 Upgrade Wells Fargo
Equal Weight → Overweight
$11 → $17
Mar-27-23 Resumed Wells Fargo
Equal Weight
$11
Jan-27-23 Upgrade Piper Sandler
Neutral → Overweight
$11 → $14
Dec-09-22 Downgrade Goldman
Buy → Neutral
$20 → $6
Oct-31-22 Initiated Guggenheim
Neutral
Aug-18-22 Resumed Wells Fargo
Equal Weight
$14
Jan-28-22 Upgrade Stifel
Hold → Buy
$23 → $25
Dec-07-21 Resumed Cowen
Outperform
Jun-10-21 Upgrade JMP Securities
Mkt Perform → Mkt Outperform
$32
May-20-21 Downgrade Piper Sandler
Overweight → Neutral
$35 → $18
May-19-21 Downgrade Stifel
Buy → Hold
May-19-21 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
May-03-21 Initiated Truist
Buy
$50
Apr-16-21 Initiated Goldman
Buy
$97
Mar-08-21 Upgrade H.C. Wainwright
Neutral → Buy
$50
Dec-15-20 Downgrade H.C. Wainwright
Buy → Neutral
Show Previous Ratings
Today 10:00AM
07:49AM
Nov-14-24 08:00AM
Nov-08-24 08:03AM
Nov-07-24 05:45PM
04:42PM
Loading…
04:42PM
(Associated Press Finance)
04:01PM
Oct-31-24 04:01PM
(GlobeNewswire) -5.43%
+7.18%
Oct-24-24 06:01PM
Oct-18-24 11:01AM
Oct-16-24 07:15PM
Oct-12-24 12:28PM
Oct-10-24 10:39AM
Oct-09-24 08:03AM
Oct-04-24 08:30AM
08:15AM
Loading…
Sep-26-24 08:15AM
Sep-16-24 06:29AM
Sep-14-24 05:32PM
Sep-06-24 09:30AM
Sep-03-24 05:00PM
Sep-02-24 06:15PM
Aug-27-24 04:36AM
Aug-16-24 05:00PM
Aug-14-24 07:15AM
Aug-09-24 12:23PM
09:27AM
Aug-08-24 05:30PM
04:24PM
(Associated Press Finance)
04:01PM
Aug-01-24 10:01AM
05:31AM
Loading…
Jul-31-24 05:31AM
Jul-29-24 06:24PM
04:01PM
08:31AM
Jul-19-24 05:00PM
Jul-17-24 02:29PM
Jul-14-24 05:45AM
Jul-11-24 02:23PM
Jul-08-24 06:46PM
12:30PM
Jun-28-24 07:00AM
04:05AM
Jun-21-24 05:00PM
06:36AM
Jun-20-24 10:02PM
08:47PM
Jun-10-24 10:15AM
May-29-24 06:20AM
04:58AM
May-28-24 08:14AM
08:06AM
May-24-24 04:01PM
11:18AM
May-23-24 05:00PM
May-22-24 06:40AM
May-17-24 05:15PM
May-16-24 09:30AM
May-13-24 02:25PM
12:42PM
May-11-24 10:00AM
May-10-24 02:03PM
01:35PM
12:55PM
12:33PM
11:25AM
10:58AM
May-09-24 08:57PM
04:27PM
(Associated Press Finance)
04:23PM
04:01PM
May-06-24 09:56AM
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
(The Wall Street Journal)
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Feb-29-24 05:47PM
12:17PM
(Thomson Reuters StreetEvents)
10:37AM
09:44AM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Maynard Ryan D Director Nov 12 '24 Option Exercise 7.45 50,000 372,500 57,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Sale 10.06 50,000 503,000 7,500 Nov 14 05:00 PM Maynard Ryan D Director Nov 12 '24 Proposed Sale 10.06 50,000 503,104 Nov 12 07:11 PM Vogt Frederick G Interim CEO & General Counsel Oct 14 '24 Option Exercise 0.00 20,834 0 213,096 Oct 16 06:33 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Oct 14 '24 Option Exercise 0.00 2,813 0 62,155 Oct 16 06:32 PM BILINSKY IGOR Chief Operating Officer Oct 14 '24 Option Exercise 0.00 2,813 0 57,235 Oct 16 06:30 PM Vogt Frederick G Interim CEO & General Counsel Sep 03 '24 Option Exercise 0.00 57,292 0 212,175 Sep 05 07:56 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Sep 03 '24 Option Exercise 0.00 27,345 0 71,233 Sep 05 07:54 PM BILINSKY IGOR Chief Operating Officer Sep 03 '24 Option Exercise 0.00 26,954 0 66,313 Sep 05 07:53 PM Bellemin Jean-Marc Chief Financial Officer Sep 03 '24 Option Exercise 0.00 23,438 0 41,239 Sep 05 07:52 PM Vogt Frederick G Interim CEO & General Counsel Jul 15 '24 Option Exercise 0.00 20,835 0 168,160 Jul 17 08:01 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jul 15 '24 Option Exercise 0.00 2,813 0 47,299 Jul 17 08:01 PM BILINSKY IGOR Chief Operating Officer Jul 15 '24 Option Exercise 0.00 2,813 0 42,571 Jul 17 08:00 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jun 03 '24 Option Exercise 0.00 3,906 0 46,468 Jun 05 08:07 PM BILINSKY IGOR Chief Operating Officer Jun 03 '24 Option Exercise 0.00 3,516 0 41,542 Jun 05 08:05 PM Vogt Frederick G Interim CEO & General Counsel Jun 03 '24 Option Exercise 0.00 10,417 0 151,751 Jun 05 08:04 PM Vogt Frederick G Interim CEO & General Counsel Apr 15 '24 Option Exercise 0.00 20,834 0 150,185 Apr 17 07:08 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Apr 15 '24 Option Exercise 0.00 2,812 0 43,989 Apr 17 07:07 PM BILINSKY IGOR Chief Operating Officer Apr 15 '24 Option Exercise 0.00 2,812 0 39,453 Apr 17 07:07 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Mar 04 '24 Option Exercise 0.00 15,623 0 49,230 Mar 06 06:20 PM Vogt Frederick G Interim CEO & General Counsel Mar 04 '24 Option Exercise 0.00 41,662 0 140,800 Mar 06 06:19 PM MCPEAK MERRILL A Director Feb 20 '24 Buy 9.15 250,000 2,287,500 320,150 Feb 20 07:52 PM Dukes Iain D. Director Feb 20 '24 Buy 9.15 32,000 292,800 54,000 Feb 20 04:21 PM Rothbaum Wayne P. Director Feb 20 '24 Buy 9.15 5,000,000 45,750,000 28,067,333 Feb 20 04:11 PM Vogt Frederick G Interim CEO & General Counsel Jan 16 '24 Option Exercise 0.00 20,834 0 105,668 Jan 18 06:09 PM GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer Jan 16 '24 Option Exercise 0.00 2,813 0 35,184 Jan 18 06:09 PM BILINSKY IGOR Chief Operating Officer Jan 16 '24 Option Exercise 0.00 2,813 0 31,444 Jan 18 06:07 PM
Index - P/E - EPS (ttm) -1.75 Insider Own 16.56% Shs Outstand 54.48M Perf Week -1.93%
Market Cap 16.74M Forward P/E - EPS next Y - Insider Trans -0.09% Shs Float 45.77M Perf Month 19.98%
Income -95.53M PEG - EPS next Q -0.38 Inst Own 24.73% Short Float 2.06% Perf Quarter -17.50%
Sales 8.69M P/S 1.93 EPS this Y - Inst Trans -25.18% Short Ratio 1.83 Perf Half Y -54.54%
Book/sh 0.01 P/B 23.67 EPS next Y - ROA -114.63% Short Interest 0.94M Perf Year -68.29%
Cash/sh 0.79 P/C 0.38 EPS next 5Y - ROE -221.25% 52W Range 0.24 - 1.31 Perf YTD -58.94%
Dividend Est. - P/FCF - EPS past 5Y -1.20% ROI -231.35% 52W High -76.71% Beta 0.65
Dividend TTM - Quick Ratio 4.71 Sales past 5Y 115.17% Gross Margin 82.71% 52W Low 27.13% ATR (14) 0.03
Dividend Ex-Date - Current Ratio 4.77 EPS Y/Y TTM 18.99% Oper. Margin -948.50% RSI (14) 51.05 Volatility 9.56% 10.06%
Employees 55 Debt/Eq 61.97 Sales Y/Y TTM -59.08% Profit Margin -1099.76% Recom 2.60 Target Price 1.00
Option/Short Yes / Yes LT Debt/Eq 57.15 EPS Q/Q 55.99% Payout - Rel Volume 0.99 Prev Close 0.31
Sales Surprise 26.80% EPS Surprise -40.70% Sales Q/Q -47.47% Earnings Aug 05 Avg Volume 513.67K Price 0.31
SMA20 -1.11% SMA50 5.88% SMA200 -40.08% Trades
Volume 508,361 Change -1.58%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-13-24 Downgrade Stifel
Buy → Hold
$6 → $1
Jun-13-24 Downgrade Needham
Buy → Hold
Jun-13-24 Downgrade H.C. Wainwright
Buy → Neutral
Jun-13-24 Downgrade Canaccord Genuity
Buy → Hold
$10 → $1
Mar-08-23 Downgrade BofA Securities
Neutral → Underperform
$13 → $6
Mar-08-22 Upgrade JP Morgan
Neutral → Overweight
$17 → $20
Nov-01-21 Resumed Canaccord Genuity
Buy
$33
Aug-03-21 Initiated JP Morgan
Neutral
$16
Apr-21-20 Reiterated H.C. Wainwright
Buy
$30 → $33
Aug-12-19 Reiterated H.C. Wainwright
Buy
$31 → $30
May-29-19 Reiterated Laidlaw
Buy
$26 → $32
Feb-06-19 Resumed Jefferies
Buy
$22
Jan-15-19 Initiated BofA/Merrill
Neutral
$19
Sep-21-18 Initiated Cantor Fitzgerald
Overweight
Sep-13-18 Initiated Jefferies
Buy
$30
Aug-08-18 Reiterated Stifel
Buy
$22 → $26
Jun-28-18 Reiterated H.C. Wainwright
Buy
$24 → $26
Mar-12-18 Resumed H.C. Wainwright
Buy
$22
Feb-12-18 Upgrade Janney
Neutral → Buy
Jan-19-18 Initiated Seaport Global Securities
Buy
$27
Show Previous Ratings
Nov-14-24 07:31PM
(Associated Press Finance)
-5.04%
Aug-15-24 01:55PM
(Associated Press Finance)
Jul-11-24 07:00AM
Jun-13-24 09:51AM
Jun-12-24 04:01PM
08:55PM
Loading…
May-13-24 08:55PM
05:10PM
04:07PM
(Associated Press Finance)
04:01PM
May-06-24 07:00AM
Apr-02-24 07:00AM
Mar-07-24 07:00AM
06:40AM
Mar-05-24 09:07AM
07:51AM
(Thomson Reuters StreetEvents)
08:51PM
Loading…
Mar-04-24 08:51PM
05:10PM
04:21PM
(Associated Press Finance)
04:01PM
Feb-12-24 04:01PM
Jan-22-24 10:19AM
07:00AM
Dec-18-23 07:00AM
Nov-14-23 11:04AM
08:48AM
(Thomson Reuters StreetEvents)
Nov-13-23 06:00PM
04:15PM
(Associated Press Finance)
04:01PM
Nov-09-23 11:38AM
Nov-06-23 10:00AM
07:00AM
Loading…
Nov-02-23 07:00AM
Oct-23-23 07:00AM
Sep-25-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 02:53AM
Aug-08-23 05:54AM
(Thomson Reuters StreetEvents)
Aug-07-23 05:15PM
04:09PM
(Associated Press Finance)
04:01PM
Aug-03-23 07:00AM
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jun-14-23 01:37PM
Jun-13-23 06:30AM
Jun-02-23 06:46PM
Jun-01-23 07:00AM
May-30-23 06:34PM
May-25-23 06:40AM
May-18-23 04:53PM
02:00AM
May-16-23 11:02AM
(Thomson Reuters StreetEvents) +7.23%
May-15-23 05:15PM
04:07PM
04:01PM
May-04-23 09:38AM
May-01-23 07:00AM
Apr-26-23 08:00PM
Apr-10-23 07:00AM
Apr-07-23 08:41AM
Mar-14-23 07:00AM
Mar-11-23 07:19AM
Mar-08-23 06:59AM
Mar-07-23 10:46AM
10:02AM
(Thomson Reuters StreetEvents)
09:43AM
08:05AM
Mar-06-23 07:39PM
05:15PM
04:01PM
Feb-27-23 10:00AM
Feb-21-23 07:00AM
Feb-15-23 05:11AM
Feb-08-23 05:00PM
Jan-17-23 07:00AM
Jan-03-23 07:00AM
Dec-29-22 05:53AM
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
04:01PM
Nov-04-22 08:46AM
Nov-03-22 07:00AM
Nov-02-22 10:01AM
07:00AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
08:15AM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
04:01PM
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Posner Christopher PRESIDENT AND CEO Nov 04 '24 Sale 0.29 3,668 1,064 168,768 Nov 06 04:51 PM Posner Christopher PRESIDENT AND CEO Aug 01 '24 Sale 0.35 4,149 1,452 172,436 Aug 02 04:05 PM Posner Christopher PRESIDENT AND CEO May 02 '24 Sale 0.75 3,936 2,952 176,585 May 06 04:15 PM Goncalves Joana CHIEF MEDICAL OFFICER Apr 05 '24 Sale 0.83 2,753 2,285 53,365 Apr 09 04:22 PM Terrillion Scott SEC'Y; CHIEF COMPLIANCE & G.C. Apr 05 '24 Sale 0.83 2,753 2,285 88,247 Apr 09 04:21 PM Terrillion Scott SEC'Y; CHIEF COMPLIANCE & G.C. Feb 29 '24 Sale 0.89 3,293 2,931 91,000 Mar 04 04:24 PM Posner Christopher PRESIDENT AND CEO Feb 29 '24 Sale 0.89 5,834 5,192 180,521 Mar 04 04:19 PM Goncalves Joana CHIEF MEDICAL OFFICER Feb 29 '24 Sale 0.89 3,293 2,931 56,118 Mar 04 04:13 PM Posner Christopher PRESIDENT AND CEO Feb 08 '24 Sale 0.53 35,575 18,855 186,355 Feb 12 05:10 PM Posner Christopher PRESIDENT AND CEO Feb 01 '24 Sale 0.55 4,981 2,740 221,930 Feb 05 04:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
